Cantor Fitzgerald Sticks to Its Buy Rating for uniQure NV (QURE)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on uniQure NV (QURE) today and set a price target of $81. The company’s shares closed yesterday at $57.10.

Piros observed:

“: We reiterate our OW rating and $81 PT on uniQure following numerous presentations at ASGCT and 1Q19 financial results. uniQure is one of our top pics of the year, and we remain confident the company could be a leader in developing hematological and CNS gene therapy candidates. We’ve also highlighted the name as a strong M&A candidate, following the Spark acquisition (note), multiple parties who were interested in Spark (note), and our full analysis on four gene therapy acquisition filings (note). Our near-term focus remains on the ongoing Phase 3 HOPE-B trial in hemophilia the next opportunity in Huntington’s disease, which is entering the clinic in 3Q19.”

According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -2.3% and a 44.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for uniQure NV with a $78.67 average price target, which is a 37.8% upside from current levels. In a report issued on April 30, H.C. Wainwright also maintained a Buy rating on the stock with a $73 price target.

See today’s analyst top recommended stocks >>

Based on uniQure NV’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $27.77 million. In comparison, last year the company had a GAAP net loss of $18.79 million.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.